Estradiol/norethisterone transdermal patch - Johnson & Johnson

Drug Profile

Estradiol/norethisterone transdermal patch - Johnson & Johnson

Alternative Names: Estradiol + norethisterone transdermal - Johnson & Johnson; Evorel Sequi; Systen Sequi

Latest Information Update: 12 Nov 1998

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Johnson & Johnson
  • Developer Janssen-Cilag
  • Class Estradiol congeners; Estrenes; Hormonal contraceptives; Hormonal replacements; Norpregnenes; Oral contraceptives; Small molecules
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Menopausal syndrome; Postmenopausal osteoporosis

Most Recent Events

  • 12 Nov 1998 Launched for Postmenopausal osteoporosis in United Kingdom (Transdermal)
  • 16 Apr 1998 A clinical study has been added to the Women's Health pharmacodynamics section
  • 15 Apr 1998 A study has been added to the Women's Health therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top